P-056: HUWE1 orchestrates DNA Repair in response to Replicative Stress in Multiple Myeloma

2021 ◽  
Vol 21 ◽  
pp. S69
Author(s):  
Jonathan Morgan ◽  
Roisin McAvera ◽  
Ken Mills ◽  
Lisa Crawford
Cancers ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 504
Author(s):  
Takayuki Saitoh ◽  
Tsukasa Oda

Multiple myeloma (MM) is an incurable plasma cell malignancy characterized by genomic instability. MM cells present various forms of genetic instability, including chromosomal instability, microsatellite instability, and base-pair alterations, as well as changes in chromosome number. The tumor microenvironment and an abnormal DNA repair function affect genetic instability in this disease. In addition, states of the tumor microenvironment itself, such as inflammation and hypoxia, influence the DNA damage response, which includes DNA repair mechanisms, cell cycle checkpoints, and apoptotic pathways. Unrepaired DNA damage in tumor cells has been shown to exacerbate genomic instability and aberrant features that enable MM progression and drug resistance. This review provides an overview of the DNA repair pathways, with a special focus on their function in MM, and discusses the role of the tumor microenvironment in governing DNA repair mechanisms.


2011 ◽  
Vol 35 (9) ◽  
pp. 1178-1183 ◽  
Author(s):  
María Teresa Cibeira ◽  
Carlos Fernández de Larrea ◽  
Alfons Navarro ◽  
Tania Díaz ◽  
Dolors Fuster ◽  
...  

2021 ◽  
Vol 13 (1) ◽  
Author(s):  
Laurie Herviou ◽  
Sara Ovejero ◽  
Fanny Izard ◽  
Ouissem Karmous-Gadacha ◽  
Claire Gourzones ◽  
...  

Abstract Background Multiple myeloma (MM) is a malignancy of plasma cells that largely remains incurable. The search for new therapeutic targets is therefore essential. In addition to a wide panel of genetic mutations, epigenetic alterations also appear as important players in the development of this cancer, thereby offering the possibility to reveal novel approaches and targets for effective therapeutic intervention. Results Here, we show that a higher expression of the lysine methyltransferase SETD8, which is responsible for the mono-methylation of histone H4 at lysine 20, is an adverse prognosis factor associated with a poor outcome in two cohorts of newly diagnosed patients. Primary malignant plasma cells are particularly addicted to the activity of this epigenetic enzyme. Indeed, the inhibition of SETD8 by the chemical compound UNC-0379 and the subsequent decrease in histone H4 methylation at lysine 20 are highly toxic in MM cells compared to normal cells from the bone marrow microenvironment. At the molecular level, RNA sequencing and functional studies revealed that SETD8 inhibition induces a mature non-proliferating plasma cell signature and, as observed in other cancers, triggers an activation of the tumor suppressor p53, which together cause an impairment of myeloma cell proliferation and survival. However, a deadly level of replicative stress was also observed in p53-deficient myeloma cells treated with UNC-0379, indicating that the cytotoxicity associated with SETD8 inhibition is not necessarily dependent on p53 activation. Consistent with this, UNC-0379 triggers a p53-independent nucleolar stress characterized by nucleolin delocalization and reduction of nucleolar RNA synthesis. Finally, we showed that SETD8 inhibition is strongly synergistic with melphalan and may overcome resistance to this alkylating agent widely used in MM treatment. Conclusions Altogether, our data indicate that the up-regulation of the epigenetic enzyme SETD8 is associated with a poor outcome and the deregulation of major signaling pathways in MM. Moreover, we provide evidences that myeloma cells are dependent on SETD8 activity and its pharmacological inhibition synergizes with melphalan, which could be beneficial to improve MM treatment in high-risk patients whatever their status for p53.


2018 ◽  
Author(s):  
Daniele Caracciolo ◽  
Martina Montesano ◽  
Emanuela Altomare ◽  
Grazia Consolo ◽  
Nicola Amodio ◽  
...  

2019 ◽  
Vol 19 (10) ◽  
pp. e79-e80
Author(s):  
Andrew Spencer ◽  
Malarmathy Ramachandran ◽  
Kawa choi ◽  
jay hocking ◽  
Daniela Klarica ◽  
...  

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3416-3416
Author(s):  
Charles A. Gullo ◽  
Feng Ge ◽  
Geraline Cow ◽  
Gerrard Teoh

Abstract Karyotypic analysis of tumor cells from patients with multiple myeloma (MM), as well as MM cell lines, frequently demonstrates numerous complex chromosomal abnormalities. Moreover, new chromosomal translocations into the switch region of the immunoglobulin heavy chain (IgH) gene (chromosome 14q32), often heralds transformation to more aggressive MM. Since DNA double stranded break repair (DSBR) is important in mediating these processes, these data suggest that abnormalities in DSBR could ultimately lead to genomic instability, clonal evolution and disease progression in MM. Truncated variants of Ku86 protein (i.e. Ku86v) have previously been detected in 86% to 100% of freshly isolated patient MM cells. Since, the Ku70/Ku86 heterodimer functions as the regulatory subunit of the DNA repair enzyme, DNA protein kinase (DNA-PK), we and others have been interested in the altered expression and function of Ku86v proteins in genome maintenance in MM. Although a number of studies have suggested that truncated forms of Ku proteins could be artificially generated by proteolytic degradation in vitro in B cells and the K562 chronic myeloid leukemia cell line, we now show using whole cell Western immunoblotting that the RPMI 8226 and SGH-MM5 human MM cell lines consistently express full-length Ku86 as well as at least 2 forms of Ku86v - a C-terminus truncated 69 kDa variant Ku86 protein (Ku86v-N); and an N-terminus truncated 56 kDa Ku86v (Ku86v-C). Expression of full-length Ku86 and Ku86v proteins was confirmed using electrophoretic mobility shift assays (EMSA) that incorporate a Ku86-specific DNA probe. In contrast, Ku86v proteins were not detected in the non-MM K562 cell line, by neither whole cell Western blotting nor EMSA, as was previously reported. These data confirm that MM cell lines contained bona fide Ku86v proteins that were generated intracellularly. However, the expected shorter mRNA transcripts of Ku86v’s were not detected using Northern blotting, indicating that Ku86v’s could have been generated by enzymatic cleavage, i.e. post-translational modification, rather than by alternative splicing. Since protease digestion of DNA protein kinase (DNA-PK) and Ku proteins is enhanced by proteasome inhibition (i.e. bortezomib treatment) in MM cell lines; these data taken in aggregate further suggest that proteolytic enzymes that are capable of digesting Ku proteins are constitutively activated, and possibly accumulate and/or become further activated under proteasome inhibition in MM cells. In order to characterize the functional role for Ku86v, we demonstrate using EMSA that both full-length Ku86 and Ku86v-N, but not Ku86v-C, are capable of binding DNA. Since the DNA binding motifs of Ku86 are located in the N-terminus, and the functional domains are located in the C-terminus, these data support the notion that whilst Ku86v-N binds DNA, it is in fact incapable of regulating DNA repair. By contrast, although Ku86v-C does not bind DNA, it may be capable of regulating other biological processes. Accordingly, we demonstrate that Ku86v-C binds to CDK4, E2F-4, BAX, Bcl2 and p53; suggesting at least a possible role for Ku86v proteins in regulating the growth and survival of MM cells. In conclusion, this study confirms that MM cells generate at least 3 forms of Ku86 protein, and that the processes of genome maintenance and/or myelomagenesis could be functionally regulated by these abnormal Ku86v proteins.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 4223-4223
Author(s):  
Stephanie Fischer ◽  
Claire Seedhouse ◽  
Thomas Schulz ◽  
Ulrich Germing ◽  
Lorenz H. Truemper ◽  
...  

Abstract The most serious long-term complications of anti-tumour therapy are secondary malignancies. After treatment of haematological malignancies such as NHL, Hodgkin’ disease and multiple myeloma as well as solid tumours like breast cancer, lung cancer, soft tissue cancer and ovarian carcinoma therapy-related leukaemia occur in 0.5 to 10% of pts. Parameters which might allow an estimation of the individual risk to develop a therapy-induced neoplasia are urgently needed. Referring to recent findings defects in the DNA-repair-system and in detoxification genes are candidate predictive factors. We have examined 125 cases of t-AML/MDS in a retrospective study. The primary neoplasias were: breast cancer (33%), NHL (22%), M. Hodgkin (7%), multiple myeloma (8%) or other miscellaneous (30%). Cytogenetic data of therapy-induced malignancies were available in 116 of 125 pts. in 66% (n=78) of whom clonal abnormalities were detected. The most frequent single abnormalities were -7/7q- (15%), inv(16)(12%), +8 (8%), t(15;17) and del(20q) (5% each). Aiming to identify possible risk factors we used this patient cohort to study genetic polymorphisms influencing the activity of DNA-repair- and detoxification enzymes. For this purpose analyses of XRCC3, RAD51, GSTT1/M1/A1/P1 and NQO1 were performed. Our patient cohort (n=125) attracted attention that patients with a deficiency for GSTT1 or with combined defects of GSTT1 and M1 had a 1.7-fold (p=0.03625) and a 2.4-fold (p=0.00921) risk resp. of developing t-AML/MDS as compared to healthy controls (n=381). Noticeable is as well that the inactivating polymorphism of GSTA1*B was significantly more frequent in the control group (p=0.01847) in comparison to our patient cohort. Subsequently we generated different categories for statistical analysis according to the primary malignancy: As yet, focusing on GSTT1/M1 revealed an overrepresentation (p<0.0005) (OR=4.0) of double null genotypes for GSTT1/M1 in pts. with t-AML/MDS after adjuvant treatment for breast cancer (n=41). Preliminary results suggest that patients with tAML/MDS following NHL (n=22) who have a defect for XRCC3 have a 4.2-fold risk to develop a tAML/MDS (p=0.02960). The polymorphism of GSTA1*B was significant only in our control group in comparison to patients who showed NHL as a primary malignancy (n=22). We suppose that in this cohort the GSTA1*B polymorphism might protect against t-AML/MDS. This could be an explanation for the overrepresentation of GSTA1*B-defect in our control group as compared to our patient cohort. Other statistical analyses did not show any significance. Taken together polymorphism of GSTA1*B and XRCC3 might be associated with the risk to develop t-AML/MDS after NHL. Defects of GSTT1 and M1 can be taken as a first hint to a risk factor for t-AML/MDS following breast cancer.


Sign in / Sign up

Export Citation Format

Share Document